- Home
- MDWD vs FRGE Comparison
MDWD vs FRGE Comparison
Compare MDWD & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- FRGE
- Stock Information
- Founded
- MDWD 2000
- FRGE 2014
- Country
- MDWD Israel
- FRGE United States
- Employees
- MDWD N/A
- FRGE 300
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- FRGE Computer Software: Prepackaged Software
- Sector
- MDWD Health Care
- FRGE Technology
- Exchange
- MDWD Nasdaq
- FRGE Nasdaq
- Market Cap
- MDWD 208.2M
- FRGE 317.7M
- IPO Year
- MDWD 2014
- FRGE N/A
- Fundamental
- Price
- MDWD $18.63
- FRGE $21.88
- Analyst Decision
- MDWD Strong Buy
- FRGE Buy
- Analyst Count
- MDWD 2
- FRGE 5
- Target Price
- MDWD $35.00
- FRGE $35.50
- AVG Volume (30 Days)
- MDWD 66.7K
- FRGE 128.4K
- Earning Date
- MDWD 08-14-2025
- FRGE 07-30-2025
- Dividend Yield
- MDWD N/A
- FRGE N/A
- EPS Growth
- MDWD N/A
- FRGE N/A
- EPS
- MDWD N/A
- FRGE N/A
- Revenue
- MDWD $19,213,000.00
- FRGE $90,840,000.00
- Revenue This Year
- MDWD $20.64
- FRGE $18.43
- Revenue Next Year
- MDWD $25.71
- FRGE $26.95
- P/E Ratio
- MDWD N/A
- FRGE N/A
- Revenue Growth
- MDWD N/A
- FRGE 14.78
- 52 Week Low
- MDWD $14.14
- FRGE $6.60
- 52 Week High
- MDWD $22.51
- FRGE $24.90
- Technical
- Relative Strength Index (RSI)
- MDWD 41.12
- FRGE 61.63
- Support Level
- MDWD $17.60
- FRGE $16.61
- Resistance Level
- MDWD $19.12
- FRGE $24.90
- Average True Range (ATR)
- MDWD 0.79
- FRGE 1.76
- MACD
- MDWD -0.15
- FRGE 0.41
- Stochastic Oscillator
- MDWD 37.84
- FRGE 63.51
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.